Ding, PengXu
Ma, Yujia
Zhu, Xiaoxia
Wu, Yijie
Ong, John
Liu, Pu
Xiao, Jiangqiang
Zhuge, Yuzheng
Funding for this research was provided by:
C. R. Bard, a wholly owned subsidiary of Becton, Dickinson and Company
Article History
Received: 13 April 2023
Accepted: 18 August 2023
First Online: 18 September 2023
Declarations
:
: All the authors declare that they have no conflict of interest.
: This study was approved by the ethics committee of Harborsite preclinical laboratory, Shanghai Harborside Medical Technology Co.,Ltd (No. IACUC-2021–052). Harborsite preclinical laboratory, certified by AAALAC (certification number: 001821), is a third party service institution in China for the animal studies in the field of medical devices. It has established a corresponding quality system according to the regulatory requirements of FDA GLP, which can meet the requirements of FDA, CE and NMPA for the registration of animal studies. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
: For this type of study, consent for publication is not required.